The Skin And Skin Structure Infections (SSSI) Caused By Bacteria drugs in development market research report provides comprehensive information on the therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and features dormant and discontinued products.
GlobalData tracks 23 drugs in development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria by 23 companies/universities/institutes. The top development phase for Skin And Skin Structure Infections (SSSI) Caused By Bacteria is preclinical with seven drugs in that stage. The Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline has 23 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline products market are: Melinta Therapeutics, Therapeutic Systems Research Laboratories and MicuRx Pharmaceuticals.
The key targets in the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline products market include Peptidoglycan (Murein), DNA Gyrase (EC 5.99.1.3), and DNA Topoisomerase IV (EC 5.99.1.3).
The key mechanisms of action in the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline product include Peptidoglycan (Murein) Inhibitor with four drugs in Pre-Registration. The Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline products include seven routes of administration with the top ROA being Intravenous and five key molecule types in the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline products market including Small Molecule, and Synthetic Peptide.
Skin And Skin Structure Infections (SSSI) Caused By Bacteria overview
Skin and Skin Structure Infections (SSSIs) caused by bacteria encompass a spectrum of infections affecting the skin and underlying tissues, varying from mild to severe and instigated by diverse bacteria. Notable culprits include Staphylococcus aureus, including methicillin-resistant strains (MRSA), Streptococcus pyogenes (group A Streptococcus), and other streptococcal species. SSSI can manifest as cellulitis, erysipelas, impetigo, folliculitis, furuncles, and abscesses, with distinct clinical presentations. Risk factors include compromised immune function, chronic conditions, skin injuries, and surgery. Diagnosis relies on clinical evaluation and occasionally laboratory tests. Antibiotics tailored to the causative bacteria are pivotal for treatment, especially in severe cases or suspected MRSA infections. Prevention involves wound care, hygiene, and managing underlying conditions to avert complications like deep tissue infections or sepsis.
For a complete picture of Skin And Skin Structure Infections (SSSI) Caused By Bacteria’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
